- Home
- WGRX vs LPTX Comparison
WGRX vs LPTX Comparison
Compare WGRX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- LPTX
- Stock Information
- Founded
- WGRX 2022
- LPTX 2011
- Country
- WGRX United States
- LPTX United States
- Employees
- WGRX N/A
- LPTX N/A
- Industry
- WGRX Other Pharmaceuticals
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WGRX Health Care
- LPTX Health Care
- Exchange
- WGRX Nasdaq
- LPTX Nasdaq
- Market Cap
- WGRX 140.2M
- LPTX 119.6M
- IPO Year
- WGRX 2025
- LPTX N/A
- Fundamental
- Price
- WGRX $4.32
- LPTX $0.31
- Analyst Decision
- WGRX
- LPTX Buy
- Analyst Count
- WGRX 0
- LPTX 2
- Target Price
- WGRX N/A
- LPTX $8.00
- AVG Volume (30 Days)
- WGRX 184.2K
- LPTX 5.8M
- Earning Date
- WGRX 01-01-0001
- LPTX 03-26-2025
- Dividend Yield
- WGRX N/A
- LPTX N/A
- EPS Growth
- WGRX N/A
- LPTX N/A
- EPS
- WGRX N/A
- LPTX N/A
- Revenue
- WGRX $18,128,831.00
- LPTX N/A
- Revenue This Year
- WGRX N/A
- LPTX N/A
- Revenue Next Year
- WGRX N/A
- LPTX N/A
- P/E Ratio
- WGRX N/A
- LPTX N/A
- Revenue Growth
- WGRX N/A
- LPTX N/A
- 52 Week Low
- WGRX $2.32
- LPTX $0.28
- 52 Week High
- WGRX $5.69
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- LPTX 25.59
- Support Level
- WGRX N/A
- LPTX $0.41
- Resistance Level
- WGRX N/A
- LPTX $0.65
- Average True Range (ATR)
- WGRX 0.00
- LPTX 0.05
- MACD
- WGRX 0.00
- LPTX 0.03
- Stochastic Oscillator
- WGRX 0.00
- LPTX 6.78
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .